Results 41 to 50 of about 14,647 (219)
Dabigatran in Cerebral Sinus Vein Thrombosis and Thrombophilia
Life, 2022 Background and Purpose: Thrombophilic gene alterations are a major risk factor for cerebral sinus vein thrombosis (CSVT). Up to 30% of all patients with cerebral sinus vein thrombosis (CSVT) are found to have thrombophilic defects such as prothrombin ...
Lukas Kellermair +5 more
doaj +1 more source
Advances in Pharmacology and Pharmacy, 2022 Dabigatran Etexilate Mesylate (DEM), a salt of prodrug dabigatran etexilate, is a potent, oral, reversible and direct thrombin inhibitor with low oral bioavailability. The present research investigation focused on the formulation of immediate release (IR)
A. Gawade +4 more
semanticscholar +1 more source
Рациональная фармакотерапия в кардиологии, 2015 According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). Aim.
Yu. B. Belousov +3 more
doaj +3 more sources
European Journal of Case Reports in Internal Medicine, 2017 Objective: To describe the benefits of reversal of the anticoagulation effects of dabigatran etexilate in patients requiring urgent surgery or thrombolysis for ischaemic stroke. Materials and methods: Four patients, treated with dabigatran etexilate and
Fredrik Andreas von Wowern +2 more
doaj +1 more source
Preclinical testing of dabigatran in trypsin-dependent pancreatitis
JCI Insight, 2022 Pancreatitis, the inflammatory disorder of the pancreas, has no specific therapy. Genetic, biochemical, and animal model studies revealed that trypsin plays a central role in the onset and progression of pancreatitis.
Zsófia Gabriella Pesei +5 more
doaj +1 more source
Synthesis of Dabigatran Etexilate
Chinese Journal of Applied Chemistry, 2013 4-Methylamino-3-nitrobenzoic acid(3) was prepared from 3-nitro-4-chlorobenzoic acid by methylamination.3-[(Pyridin-2-yl)amino]propinoic acid ethyl ester(5) was prepared from 2-aminopyridine and ethyl acrylate by Michael addition.Dabigatran etexilate was synthesized from compounds 3 and 5 via condensation,catalytic hydrogenation,acylation with N-(4 ...
Chen Guo-hua, Liu Xiaojun
openaire +2 more sources
Determination of Dabigatran Concentration in Human Plasma and Breast Milk
International Journal of Analytical Chemistry, 2021 Venous thromboembolism (VTE) is an important cause of death following childbirth. Dabigatran etexilate can be a useful prophylaxis in susceptible women during the postpartum period. However, it is not clear whether dabigatran is excreted into breast milk
F. Sidgwick +4 more
doaj +1 more source
Use of idarucizumab for emergency surgery in patients taking dabigatran
Атеротромбоз, 2022 This article presents modern possibilities for the provision of emergency surgical care to patients with atrial fibrillation, who administered dabigatran etexilate.
O. M. Nesterova +5 more
doaj +1 more source
A Patient's Guide to Taking Dabigatran Etexilate [PDF]
Circulation, 2011 Dabigatran etexilate is a prescription medication used to slow and inhibit the formation of blood clots. Dabigatran is known by the trade name Pradaxa in the United States and all other countries in which it is marketed except Japan (Prazaxa) and Canada (Pradax).
Vincent J. Willey, Sarah A. Spinler
openaire +3 more sources
In Vitro and Clinical Evaluations of UGT1A1-, P-gp-, OATP1B1-, and BCRP-Mediated Drug-Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor. [PDF]
J Clin PharmacolAbstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Schueller O +4 more
europepmc +2 more sources